Accessibility Menu
TransCode Therapeutics logo

TransCode Therapeutics(NASDAQ) RNAZ

Current Price$6.19
Market Cap$7.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)-100%
5 Year-100%
1 Year-36%
1 Month+49%
TransCode Therapeutics last closing stock price
MetricPriceDate
Last closeUSD 7.252026-07-23
TransCode Therapeutics stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-12.33%USD 8.272026-07-16
1 month+49.33%USD 4.862026-06-23
3 month-14.91%USD 8.522026-04-24
Year to date+6.15%USD 6.832025-12-31
1 year-35.67%USD 11.272025-07-23
3 year-99.99%USD 85,747.202023-07-24
5 year-100%USD 2,505,888.002021-07-23
Since inception-100%USD 3,910,408.042021-07-09

TransCode Therapeutics Financials at a Glance

Market Cap

$7.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$0.00

Net Income (TTM)

-$40.36M

EPS (TTM)

-$48.65

P/E Ratio

-0.15

Dividend

$0.00

Beta (Volatility)

1.49 (Average)

Price

$6.19

Volume

722

Open

$6.23

Previous Close

$6.19

Daily Range

$5.83 - $6.23

52-Week Range

$3.82 - $20.99

Estimated Earnings Date

Aug 18, 2026

RNAZ News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About TransCode Therapeutics

TransCode develops drugs to help doctors find and treat cancer that has spread. Its main products aim to target cancer cells using new RNA-based technology. These solutions are designed for patients with advanced cancer and the doctors treating them.

Lab Bench to Bedside: Products and Services

  • TTX-MC138 (Lead Drug): An experimental drug for treating metastatic (spreading) cancer; no revenue generated.
  • TTX-siPDL1: A drug candidate aiming to block a protein that helps cancer cells avoid the immune system.
  • TTX-siLIN28B: A drug candidate targeting a protein linked to cancer growth.
  • TTX-RIGA: A therapy designed to boost the body’s immune response against tumors.
  • TTX-CRISPR: A platform using gene-editing tools to target cancer genes inside tumor cells.
  • TTX-mRNA: A platform for developing cancer vaccines to help the immune system attack tumors.

Growth and Expansion: The RNA Roadmap

  • Launched Phase I/II clinical trial for TTX-MC138 in 2024.
  • Amended collaboration with MD Anderson Cancer Center in 2024, focusing on clinical trial participation.
  • Received a $1,999,972 NIH grant in September 2024 to support clinical trials.
  • Reduced headcount and operating expenses in 2025 to extend cash runway.

What Makes TransCode Stand Out in the Crowd

TransCode uses iron oxide nanoparticles to deliver RNA drugs directly to tumors, allowing for targeted treatment and MRI tracking. Its modular technology can be adapted for different cancer targets and therapies. The company focuses on hard-to-treat cancers that lack effective drug options.

Five Things You Need to Know

  • Revenue was $0 in Q2 2025, unchanged from Q2 2024 and Q2 2023.
  • Cash was $7.4 million as of June 30, 2025, up from $5.8 million at year-end 2024.
  • Net loss was $16.4 million in H1 2025, up from $8.5 million in H1 2024.
  • Headcount was 7 full-time employees as of June 30, 2025, down from prior periods.

Bottom Line

TransCode remains a pre-revenue biotech focused on RNA-based cancer therapies. The company faces ongoing financial challenges but continues to advance its clinical programs and adapt its operations.

AI Generated • Apr 16, 2026

Industry

Biotechnology

Sector

Health Care

Employees

12

CEO

Philippe P. Calais, PhD

Website

www.transcodetherapeutics.com

Headquarters

Boston, MA 02109, US

RNAZ Financials

Key Financial Metrics (TTM)

Gross Margin

0.00%

Operating Margin

0.00%

Net Income Margin

0.00%

Return on Equity

-99.39%

Return on Capital

-270.72%

Return on Assets

-25.68%

Earnings Yield

-6.67%

Dividend Yield

0.00%

Payout Ratio

-42.75%

Stock Overview

Market Cap

$7.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

1.06M

Volume

722

Avg. Volume

59.76K

Financials (TTM)

Gross Profit

-$28.72K

Operating Income

-$32.14M

EBITDA

-$39.81M

Operating Cash Flow

-$4.99B

Capital Expenditure

-$6.66K

Free Cash Flow

-$4.99B

Cash & ST Invst.

$12.84M

Total Debt

$0.00

TransCode Therapeutics Performance Analysis

TransCode Therapeutics annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 0N/A
20232023-12-31USD 0N/A
20242024-12-31USD 0N/A
20252025-12-31USD 0N/A
TransCode Therapeutics sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30N/A
Q42025-12-31N/A
Q12026-03-31N/A
TransCode Therapeutics annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1,000,521.99155.2%
20232023-12-31USD -95,731.94-90.4%
20242024-12-31USD -1,317.38-98.6%
20252025-12-31USD -52.59-96.0%
TransCode Therapeutics sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3092.7%
Q32025-09-30-13.5%
Q42025-12-31-182.1%
Q12026-03-31-29.6%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$0.00

N/A

Gross Profit

-$23.94K

N/A

Gross Margin

0.00%

N/A

Market Cap

$7.67MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$639.50K

N/A

Employees

12

N/A

Net Income

-$17.79M

-47.2%

EBITDA

-$17.53M

-45.7%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$12.84M

+10.9%

Total Debt

$0.00

N/A

Accounts Receivable

$2.30M

+612.8%

Inventory

$0.00

N/A

Long Term Debt

$0.00

N/A

Short Term Debt

$0.00

N/A

Return on Assets

-25.68%

N/A

Return on Invested Capital

-21.17%

N/A

Free Cash Flow

-$4.98B

-160638.4%

Operating Cash Flow

-$4.98B

-160638.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BOLTBolt Biotherapeutics, Inc.
$3.83+0.52%
APVOAptevo Therapeutics Inc.
$4.39+0.46%
APREAprea Therapeutics, Inc.
$0.63+0.16%
KPRXKiora Pharmaceuticals, Inc.
$2.55+2.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.42-0.04%
ONDSOndas
$7.80-0.02%
AALAmerican Airlines Group
$14.48+0.07%
CLFCleveland-Cliffs
$11.93+0.09%

Questions About RNAZ

What is the current price of TransCode Therapeutics?

TransCode Therapeutics is trading at $6.19 per share.

What is the 52-week range for TransCode Therapeutics?

Over the past 52 weeks, TransCode Therapeutics has traded between $3.82 and $20.99.

How much debt does TransCode Therapeutics have?

As of the most recent reporting period, TransCode Therapeutics reported total debt of $0.00.

How much cash does TransCode Therapeutics have on hand?

TransCode Therapeutics reported $12.84M in cash and cash equivalents in its most recent financial results.

What is TransCode Therapeutics’s dividend yield?

TransCode Therapeutics does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services